GlobeNewswire: Safetek International Inc. Contains the last 10 of 3 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T04:32:07ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2005/06/30/329600/80900/en/Safetek-SFIN-Applies-to-Be-Listed-on-OTC-Bulletin-Board.html?f=22&fvtc=4&fvtv=3840Safetek 'SFIN' Applies to Be Listed on OTC Bulletin Board2005-06-30T19:00:00Z<![CDATA[
NEW YORK, June 30, 2005 (PRIMEZONE) -- Safetek International, Inc. (Pink Sheets:SFIN) announced today that a Form 211 application has been filed with the NASD on the Company's behalf for the listing of its common stock on the "Over-The-Counter Bulletin Board" (OTC BB).
]]>https://www.globenewswire.com/news-release/2005/05/23/327855/78719/en/Safetek-Announces-New-Life-Sciences-Direction.html?f=22&fvtc=4&fvtv=3840Safetek Announces New Life Sciences Direction2005-05-23T20:14:19Z<![CDATA[
NEW YORK, May 23, 2005 (PRIMEZONE) -- On May 4, 2005, the Company (Pink Sheets:SFIN) resolved to focus on new technologies in the life sciences and health care fields. Despite the considerable medical advances that have occurred over the last few decades, there still remain major areas of unmet need. To date, Safetek has identified several innovative drug discovery, drug development and medical device technologies that may be used to create effective therapeutics for the treatment of various diseases.
]]>https://www.globenewswire.com/news-release/2005/05/23/327849/78712/en/Safetek-SFIN-Announces-New-Director-CEO.html?f=22&fvtc=4&fvtv=3840Safetek -- SFIN -- Announces New Director/CEO2005-05-23T19:02:02Z<![CDATA[
NEW YORK, May 23, 2005 (PRIMEZONE) -- On April 19, 2005, the Company announced the election of Dr. Shay Goldstein as new Director and CEO of Safetek International (Pink Sheets:SFIN). Dr. Goldstein brings to Safetek in-depth medical scientific understanding as well as his experience in developing business strategy and managing growing companies. He has held a variety of business development and operational executive positions with numerous biomedical companies. Prior to joining Safetek, Dr. Goldstein spent 3 years in Silicon Valley, California, as the director of Rimed, Ltd., an Israeli based medical devise company specializing in development of advanced Neuro-diagnostic medical equipment. He established the marketing and sales infrastructure of that company in the U.S. and was responsible for growing the market share from 0% to 14% in the first year of operation. During that period Dr. Goldstein also served as a Life Science Consultant for Silicon Ventures. As an advisor to one of the largest organized groups of Angel Investors in the United States, he provided clinical and business analysis for several medical device and biotechnology projects. Prior to that Dr. Goldstein served 2 years as the business development and medical marketing director at Medidactic, Ltd, both in the U.S. and in Israel. At Medidactic, he managed marketing and sales training projects for several leading healthcare companies internationally, including: "Teva" (Israel), "Roche" (Israel), "Taro" (Israel), "Advanced Stent Technologies (USA) and "Corgentech" (USA). Earlier in his career, Dr. Goldstein was a Co-Founder and Manager of a biotechnology Incubator project that developed a biochemical delivery system for treating Neurodegenerative diseases. Dr. Goldstein received his MD and B.Sc in Medical sciences (Cum Laude) degrees from the Technion, Israel Institute of Technology.
]]>